Velcade (bortezomib) is a proteasome inhibitor that has been approved for use in certain cancers, and has been shown useful for other cardiovascular and inflammatory diseases.
One of the most dangerous results of traumatic brain injury is the inflammation that can occur directly after injury. As a proteasome inhibitor, Velcade has the potential to regulate such inflammatory responses, and may therefore be of benefit to survivors of traumatic brain injury.
In a recent animal study, Velcade (administered 2 hours after injury) was found to significantly decrease inflammation, lesion volume, and functional deficits. Although Velcade has the potential to be a useful treatment for traumatic brain injury, it will need further clinical study to determine dosage.
Qu C, Mahmood A, Ning R, et al. The treatment of traumatic brain injury with Velcade. Journal of Neurotrauma. (August 2010).